Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors

Article abstract of DOI:10.1016/j.chembiol.2020.10.001

Castration-resistant prostate cancers (CRPCs) lose sensitivity to androgen-deprivation therapies but frequently remain dependent on oncogenic transcription driven by the androgen receptor (AR) and its splice variants. To discover modulators of AR-variant activity, we used a lysate-based small-molecule microarray assay and identified KI-ARv-03 as an AR-variant complex binder that reduces AR-driven transcription and proliferation in prostate cancer cells. We deduced KI-ARv-03 to be a potent, selective inhibitor of CDK9, an important cofactor for AR, MYC, and other oncogenic transcription factors. Further optimization resulted in KB-0742, an orally bioavailable, selective CDK9 inhibitor with potent anti-tumor activity in CRPC models. In 22Rv1 cells, KB-0742 rapidly downregulates nascent transcription, preferentially depleting short half-life transcripts and AR-driven oncogenic programs. In vivo, oral administration of KB-0742 significantly reduced tumor growth in CRPC, supporting CDK9 inhibition as a promising therapeutic strategy to target AR dependence in CRPC. In the pursuit of hormone receptor modulators in prostate cancer, a potent, ultraselective CDK9 inhibitor is discovered. This study describes the most selective inhibitors of CDK9 known to date and provides compelling preclinical in vitro and in vivo support for CDK9 as a therapeutic target.

Full text of DOI:10.1016/j.chembiol.2020.10.001

Cytotherapy (ISSN 1465-3249) is published 12 times a year on behalf of the Inter-
national Society for Cell & Gene Therapy by Elsevier Inc, 230 Park Avenue,
Suite 800, New York, NY 10169-0901, USA.
Photocopying. Single photocopies of single articles may be made for personal use
as allowed by national copyright laws. Permission of the Publisher and payment
of a fee is required for all other photocopying, including multiple or systematic
copying, copying for advertising or promotional purposes, resale, and all forms of
document delivery. Special rates are available for educational institutions that
wish to make photocopies for non-profit educational classroom use.
USA POSTMASTER: Send address changes to Cytotherapy, Journal Returns,
1799 Highway 50 East, Linn, MO 65051, USA.
CUSTOMER SERVICE (orders, claims, online, change of address): Elsevier
Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane,
Maryland Heights, MO 63043. Tel: (800) 654-2452 (U.S. and Canada); (314)
Permissions may be sought directly from Elsevier’s Rights Department in
Oxford, UK: +44 (0) 1865 843830, fax +44 (0) 1865 853333, e-mail healthper-
missions@ elsevier.com. Requests may also be completed online via the Elsevier
homepage (http://www.elsevier.com/locate/permissions).
447-8871 (outside U.S. and Canada). Fax: (314) 447-8029. E-mail: Journals-
CustomerService-usa@elsevier.com (for print support); JournalsOnlineSuppor-
tusa@elsevier.com (for online support). Address changes must be submitted four
weeks in advance.
In the USA, users may clear permissions and make payments through the Copy-
right Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA;
phone: (978) 750-8400, fax: (978) 750-4744, and in the UK through the Copyright
Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court
Road, London W1P 0LP, UK; phone: (+44) 20 7631 5555; fax: (+44) 20 7631
YEARLY SUBSCRIPTION RATES: Individual Non-US $449; Individual US
$449; Student/Resident Non-US $449; Student/Resident US $449. To receive
student/resident rate, orders must be accompanied by name of affiliated institu-
tion, date of term and the signature of program/residency coordinator on institu-
tion letterhead. Orders will be billed at the individual rate until proof of status is
received. Current prices are in effect for back volumes and back issues.
5
500. Other countries may have a local reprographic rights agency for payments.
Derivative Works. Subscribers may reproduce tables of contents or prepare lists of
articles including abstracts for internal circulation within their institutions. Permis-
sion of the Publisher is required for resale or distribution outside the institution.
Further information on this journal is available from the Publisher or from this
journal’s website (www.isct-cytotherapy.org). Information on other Elsevier
products is available through Elsevier’s website (http://www.elsevier.com).
Permission of the Publisher is required for all other derivative works, including
compilations and translations.
Advertising information. Advertising and classified advertising orders and inquiries
can be sent to: Jonathan Christison, jchristison@cell.com USA, Canada and South
America: Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169-0901,
USA; phone: (+1) (212) 989 5800; Europe and ROW, phone +44 (0) 1865
Electronic Storage or Usage. Permission of the Publisher is required to store or
use electronically any material contained in this journal, including any article or
part of an article.
843016; fax +44 (0) 1865 843976; e-mail media@elsevier.com.
Except as outlined above, no part of this publication may be reproduced, stored
in a retrieval system or transmitted in any form or by any means, electronic,
mechanical, photocopying, recording or otherwise, without prior written permis-
sion of the Publisher.
Author inquiries. Please see Information for Authors at http://www.isct-
cytotherapy.org/authorinfo. For other inquiries relating to the submission of
articles, visit http://www.elsevier.com/authors. The site also provides the facility
to track accepted articles and set up e-mail alerts to inform you of when an
article’s status has changed, as well as detailed artwork guidelines, copyright
information, frequently asked questions, and more. Contact details for ques-
tions arising after acceptance of an article, especially those relating to proofs,
are provided after registration of an article for publication.
Address permissions requests to: Elsevier Rights Department, at the fax and email
addresses noted above.
Abstracting and Indexing. Cytotherapy is indexed in PubMed/Medline, Current
Contents - Clinical Medicine, Current Contents - Life Sciences and Clinical
Medicine, BIOSIS Citation Index, Science Citation Index Expanded, Embase,
Scopus, and Journal Citation Reports - Science Edition.
English language help service: Upon request, Elsevier will direct authors to an
agent who can check and improve the English of their paper (before submission).
Please contact authorsupport@elsevier.com for further information.
For queries about author offprints, e-mail authorsupport@elsevier.com. To order
Notice. No responsibility is assumed by the Publisher or the International Society
for Cell & Gene Therapy for any injury and/or damage to persons or property as a
matter of products liability, negligence or otherwise, or from any use or operation
of any methods, products, instructions or ideas contained in the material herein.
Because of rapid advances in the medical sciences, in particular, independent ver-
ification of diagnoses and drug dosages should be made.
1
00 or more reprints for educational, commercial, or promotional use, contact
Derrick Imasa at 212-633-3874, Elsevier Inc., 230 Park Avenue, Suite 800, New
York, NY 10169-0901, USA; e-mail reprints@elsevier.com. Reprints of single
articles available online may be obtained by purchasing Pay-Per-View access for
$31.50 per article on the journal website www.isct-cytotherapy.org.
Ó 2020 International Society for Cell & Gene Therapy. All rights reserved.
Although all advertising material is expected to conform to ethical (medical)
standards, inclusion in this publication does not constitute a guarantee or
endorsement of the quality or value of such product or of the claims made of it by
its manufacturer.
This journal and the individual contributions contained in it are protected under
copyright by International Society for Cell & Gene Therapy, and the following
terms and conditions apply to their use: